Our Pricing

Side Effects Wegovy Starter Dose: Your First Month Guide

Published on: June 03, 2026

Understanding wegovy starter dose side effects uk patterns helps you navigate your first month with confidence. At Cured Pharmacy, our UK clinical team has supported thousands of patients through their Wegovy journey, and we've compiled this evidence-based guide to help you manage the 0.25mg starter dose effectively. Most side effects are mild, temporary, and manageable with the right strategies.

What Is the Wegovy Starter Dose and Why Does It Matter?

Wegovy's starter dose is 0.25mg once weekly for the first four weeks. This graduated dosing schedule isn't arbitrary — it's designed to minimise gastrointestinal side effects whilst your body adapts to semaglutide [1]. The STEP clinical trials demonstrated that slow dose escalation significantly reduces the incidence of severe nausea and vomiting compared to starting at higher doses.

Semaglutide works by mimicking GLP-1, a naturally occurring hormone that slows gastric emptying and increases satiety signalling. Your digestive system needs time to adjust to this altered pace, which is why the starter dose is intentionally sub-therapeutic for weight loss [1]. You're unlikely to see significant weight reduction in month one — the focus is on tolerability and establishing your injection routine.

The full Wegovy dose escalation follows this schedule: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1.0mg (weeks 9-12), 1.7mg (weeks 13-16), and finally 2.4mg maintenance dose from week 17 onwards. Each step allows your body to adapt gradually, reducing the likelihood of discontinuation due to side effects [2].

Common Wegovy Starter Dose Side Effects: What to Expect in Month One

In the STEP-1 trial, gastrointestinal side effects were reported by approximately 74% of participants, with the majority occurring during dose escalation phases [1]. At the 0.25mg starter dose, the most frequently reported side effects include nausea (affecting 20-25% of patients), mild constipation, occasional diarrhoea, and reduced appetite.

Nausea typically peaks 2-3 days after your first injection and gradually improves as your body adapts. Most patients report that nausea at the starter dose is manageable without medication and doesn't interfere with daily activities. Fatigue and mild headaches affect approximately 10-15% of patients during the first fortnight but usually resolve by week three [2].

It's important to distinguish between expected side effects and serious adverse reactions. Contact your prescriber immediately if you experience severe abdominal pain (particularly upper right quadrant pain), persistent vomiting that prevents fluid intake, visual changes, or signs of pancreatitis. These occur rarely but require prompt medical assessment.

When Side Effects Peak and Subside

Side effects follow a predictable pattern. Nausea and digestive changes are most pronounced in the 48-72 hours following your weekly injection, then gradually diminish until your next dose. By week three or four of the starter dose, most patients report minimal symptoms even immediately post-injection. This adaptation continues throughout dose escalation — what feels uncomfortable at 0.25mg becomes your new baseline, making the step to 0.5mg more tolerable.

Evidence-Based Strategies to Manage Wegovy Starter Dose Side Effects

Dietary modifications significantly reduce gastrointestinal symptoms during the starter dose phase. Clinical experience shows that smaller, more frequent meals (5-6 times daily) are better tolerated than three large meals. Avoid high-fat foods for the first 72 hours after each injection, as delayed gastric emptying makes fatty meals particularly likely to trigger nausea [3].

Hydration is critical but requires strategy. Sip fluids throughout the day rather than drinking large volumes at once. Cold, clear liquids are generally better tolerated than warm drinks during peak nausea periods. Ginger tea, peppermint tea, and electrolyte solutions can help manage mild nausea without medication.

Injection timing matters more than many patients realise. If you experience evening nausea, consider injecting before bedtime so peak side effects occur whilst you sleep. Conversely, if fatigue is your primary concern, morning injections allow you to rest during the afternoon dip. There's no single optimal time — individualise based on your symptom pattern.

Foods That Help and Foods to Avoid

During your first month, prioritise bland, protein-rich foods: plain chicken, white fish, eggs, Greek yoghurt, and well-cooked vegetables. These provide nutrition without triggering nausea. Avoid triggers including fried foods, rich sauces, carbonated drinks, alcohol, and highly spiced dishes. Many patients find that cold foods (smoothies, chilled fruit, salads) are easier to tolerate than hot meals during the first week after each injection.

Managing Nausea: The Most Common Wegovy Starter Dose Challenge

Nausea is the most frequently cited reason for Wegovy discontinuation, yet it's highly manageable with proactive strategies [2]. If dietary modifications aren't sufficient, speak with your prescriber about anti-emetic options. Prochlorperazine (Stemetil) or domperidone may be prescribed for short-term use during dose escalation.

Non-pharmacological approaches include acupressure wristbands (P6 point stimulation), which some patients find helpful. Avoid lying flat within three hours of eating, as this exacerbates reflux and nausea. If you vomit within four hours of taking other oral medications, contact your prescriber as absorption may be affected.

Persistent severe nausea lasting beyond 72 hours post-injection or interfering with adequate hydration warrants clinical review. Your prescriber may recommend remaining at the current dose for an additional month before escalating, or in rare cases, switching to an alternative GLP-1 treatment with a different side effect profile.

Wegovy Starter Dose Side Effects vs Higher Doses: What Changes

The 0.25mg starter dose produces the mildest side effect profile across the entire Wegovy treatment course. As you escalate to 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg, the intensity and duration of side effects typically increase with each step [1]. However, patients who tolerate the starter dose well generally continue to tolerate higher doses, as each escalation builds on established adaptation.

Interestingly, some side effects become less problematic at higher doses. Appetite suppression, barely noticeable at 0.25mg, becomes therapeutic at 1.7mg and above. Conversely, constipation may worsen with dose escalation and require ongoing management with increased fibre, hydration, and occasionally stool softeners.

The STEP trials showed that discontinuation rates due to gastrointestinal side effects were highest during the transition from 1.0mg to 1.7mg, not during the starter dose phase [2]. This underscores the importance of mastering side effect management strategies early, during the gentler 0.25mg phase, so you're prepared for subsequent escalations.

Why the Starter Dose Feels Different

At 0.25mg, you're receiving approximately 10% of the therapeutic maintenance dose. Many patients report feeling 'something' but not dramatic effects — perhaps mild appetite reduction or slight digestive changes. This is exactly as intended. The starter dose serves as physiological preparation, not clinical treatment. Weight loss during month one is typically modest (1-2kg on average), with most reduction attributable to reduced food intake rather than the metabolic effects seen at higher doses [3].

When to Contact Your Prescriber About Wegovy Starter Dose Side Effects

Most starter dose side effects are self-limiting and don't require medical intervention, but certain symptoms warrant prompt clinical review. Contact your prescriber if you experience severe, persistent abdominal pain, especially if localised to the upper abdomen and radiating to the back — this may indicate pancreatitis, a rare but serious complication [2].

Persistent vomiting (more than 24 hours) that prevents adequate fluid intake requires assessment for dehydration and potential dose adjustment. Similarly, if you develop visual changes, symptoms of gallbladder disease (right upper quadrant pain, jaundice), or signs of acute kidney injury (significantly reduced urination, swelling), seek medical advice promptly.

Less urgent but still important: if side effects aren't improving by week three of the starter dose, or if they're significantly impacting your quality of life, discuss options with your prescriber. Remaining at 0.25mg for an additional month, adjusting injection timing, or adding supportive medications are all valid strategies. At Cured Pharmacy, our clinical team is available to review your progress and adjust your treatment plan as needed — all prescription adjustments are subject to prescriber approval following clinical assessment.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 0.25 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine licensed by the MHRA for weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities, alongside a reduced-calorie diet and increased physical activity. Individual results may vary. Side effects can occur — read the patient information leaflet carefully and contact your prescriber if you experience concerning symptoms.